In this week’s View, Dr. Eagle discusses the European Atherosclerosis Society’s consensus statement on lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, then looks at CHD Screening in Kidney and Liver Transplant Candidates.

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Atherosclerotic Disease (CAD/PAD), Lipid Metabolism, Nonstatins, Novel Agents, Statins, Interventions and Coronary Artery Disease, Interventions and Structural Heart Disease, Prevention

Keywords: EaglesEyeView, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering, Cholesterol, LDL, Antifibrinolytic Agents, Cardiovascular Diseases, Coronary Artery Disease, Aortic Valve Stenosis, Heart Disease Risk Factors, Hepatocytes, End Stage Liver Disease, Liver Transplantation, Platelet Aggregation Inhibitors, Kidney Transplantation, Cytidine Triphosphate, Dobutamine, Non-alcoholic Fatty Liver Disease, Renin-Angiotensin System, Percutaneous Coronary Intervention

< Back to Listings